2012~ THE 2ND LAPR,  ACHIEVE 200 BILLION IN SALES AND BECOME A COMPANY WORK FOR AND RESPECTED

2024

Myeongmun Fentanyl Patch Joint Marketing Agreement Signed (Myungmoon Pharmaceutical)

Technology transfer for generic development of stafen for use in complex dyslipidemia (JP Bio)

Signed an exclusive domestic sales contract for the generic version of iron deficiency treatment drug (Perinject) / Huiwei Pharmaceutical (China)

Ministry of Health and Welfare Innovative Pharmaceutical Company 5th Recertification (June 20, 2024 ~ June 19, 2027)

Exclusive domestic sales contract for narcotic analgesic (Nucynta) / Grunenthal GmbH (Germany)

Technology transfer for development of generic version of antiulcer drug Noltec (Vaxcell-Bio)

Sialanar (pediatric medicine) Exclusive supply agreement / Proveca (UK) (BC World Healthcare)

2023

Anti-Corruption Management System ISO 37001 Renewal

Signing of contract for digital marketing and distribution service agency using pharmaceutical direct transaction platform (BlueMTech)

Digital Therapeutics and Wellness Applications Joint Development Agreement (All Around Doctors)

Signing of a joint development and domestic exclusive sales contract for a medical device (Hydrafill) for the treatment of degenerative lumbar disc disease / ReGelTec (USA) (BC World Healthcare)

2022

Completing building Pangyo headquarter

Approved BCWP_IND

2021

Selected as a small and medium-sized company for human resource development

Ministry of Health and Welfare recertified for the 3rd time as an innovative pharmaceutical company

Approved as Korea's first rosuvastatin oral disintegrating tablet "Suvaro Odi Tablet"

2020

Awarded the 5-million USD export tower

Ministry of Gender Equality and Family certified as a family-friendly company

Ministry of SMEs and Startups selected as a management innovation-type SME (Main-Biz)

Korea Productivity Center certified it as a productivity management system

Price listed of Mepem Q Inj. 1 g and Mepem Q Inj.500 mg (BC World Healthcare)

Acquired KGMP certification (BC World Healthcare)

2019

Certified ISO37001

Registered in a European patent, the preparation method of drug-containing sustained release microparticles

2018

Registered in a European patent, the preparation method of drug-containing sustained release microparticles

Registered in Chile patent, the new methods and apparatus for preparing liposomes

KOTRA selected as a 2018’s leading export company in the pharmaceutical sector

2017

Awarded Korea Technology Promotion Contributors Awards

Purchased the site for the 2nd factory in Wonju Enterprise City

2016

Small and Medium Business Administration selected as a small and medium-sized business innovation development project

Ministry of Health and Welfare awarded as an excellent innovative pharmaceutical company

Ministry of Trade, Industry and Energy has selected as a material and parts technology development project

Completed Yeoju global new factory (acquired approval for use)

2015

Signed SEP Microsphere licensing out contract with Akorn (USA)

Ministry of Health and Welfare recertified as an innovative pharmaceutical company

2014

Listed on the KOSDAQ of the Korea Exchange

Small and Medium Business Administration awarded CEO Hong Seong-han for the Proud Small Business Person Award

2013

Started construction of EU-GMP / cGMP plant

2012

Awarded 3 million USD export tower

Awarded President’s Award for the contribution to venture vitalization

Ministry of Knowledge Economy designated as an Excellent Technology Research Center (ATC)

Ministry of Health and Welfare certified as an innovative pharmaceutical company

Established GRI (Global Research Institute)

1999 ~ 2007 STRIVING TO BECOME A
'R&D-ORIENTED, RESPECTED GLOBAL PHARMACEUTICAL COMPANY'

2007

Changed company name to BC WORLD PHARMACEUTICAL

Acquired INNO-BIZ certification (Small and Medium Business Administration)

2006

Inauguration of CEO Hong Sung-han (acquisition of shares)

1999

Established the Central Research Center (Yeoju factory)